Abstract
Background and AimLittle is known about the tolerability of antihypertensive drugs during hemodialysis treatment. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan.DesignRandomized, double-blind, placebo-controlled, one-year intervention trial.Setting and ParticipantsEighty-two hemodialysis patients with urine output >300 mL/day and dialysis vintage <1 year.InterventionIrbesartan/placebo 300 mg/day for 12 months administered as add-on to antihypertensive treatment using a predialytic systolic blood pressure target of 140 mmHg in all patients.Outcomes and MeasurementsCardiac output, stroke volume, central blood volume, total peripheral resistance, mean arterial blood pressure, and frequency of intradialytic hypotension.ResultsAt baseline, the groups were similar regarding age, comorbidity, blood pressure, antihypertensive medication, ultrafiltration volume, and dialysis parameters. Over the one-year period, predialytic systolic blood pressure decreased significantly, but similarly in both groups. Mean start and mean end cardiac output, stroke volume, total peripheral resistance, heart rate, and mean arterial pressure were stable and similar in the two groups, whereas central blood volume increased slightly but similarly over time. The mean hemodynamic response observed during a dialysis session was a drop in cardiac output, in stroke volume, in mean arterial pressure, and in central blood volume, whereas heart rate increased. Total peripheral resistance did not change significantly. Overall, this pattern remained stable over time in both groups and was uninfluenced by ARB treatment. The total number of intradialytic hypotensive episodes was (placebo/ARB) 50/63 (P = 0.4). Ultrafiltration volume, left ventricular mass index, plasma albumin, and change in intradialytic total peripheral resistance were significantly associated with intradialytic hypotension in a multivariate logistic regression analysis based on baseline parameters.ConclusionUse of the ARB irbesartan as an add-on to other antihypertensive therapy did not significantly affect intradialytic hemodynamics, neither in short nor long-term, and no significant increase in hypotensive episodes was seen.Trial registrationClinicaltrials.gov NCT00791830
Highlights
Hemodynamic instability is reported to occur in 4–30% of hemodialysis (HD) treatments [1,2,3,4]
The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan
The mean hemodynamic response observed during a dialysis session was a drop in cardiac output, in stroke volume, in mean arterial pressure, and in central blood volume, whereas heart rate increased
Summary
Hemodynamic instability is reported to occur in 4–30% of hemodialysis (HD) treatments [1,2,3,4]. The risk of instability may increase due to predisposing factors such as heart disease, diabetes, old age, atherosclerosis, food ingestion during dialysis, impaired sympathetic response, and antihypertensive medication [2, 9,10,11]. These factors should be considered in patients prone to IDH regardless of UF volume. The present study evaluated the use of the angiotensin II receptor blocker (ARB) irbesartan
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
